ARF5 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-cell leukemia line, featuring targeted disruption of the ARF5 gene. This loss-of-function model enables investigation of ARF5-dependent intracellular trafficking and secretory processes without the confound of monoclonal selection artifacts. The polyclonal nature reflects the heterogeneous editing outcomes inherent to CRISPR/Cas9-mediated gene disruption, providing a robust experimental system for studying endogenous Golgi-to-ER retrograde transport and related cellular phenotypes in a T-lymphocyte context.
Jurkat cells, originally isolated from an acute T-cell leukemia patient and represented by the E6-1 clone, constitute a widely used T-lymphocyte model in immunology and cancer research. These cells exhibit key characteristics of activated T cells, including robust cytokine secretion, receptor-mediated signaling, and susceptibility to apoptosis, making them suitable for dissecting pathways central to adaptive immunity and leukemogenesis. Their leukemic origin further positions them as a relevant platform for exploring oncogenic signaling and drug-response mechanisms.
ARF5 encodes a small GTPase of the ARF family that acts as a molecular switch in COPI-mediated vesicle formation. Upon activation by the guanine nucleotide exchange factor GBF1 at the Golgi membrane, ARF5 exchanges GDP for GTP and undergoes a conformational change that facilitates recruitment of the coatomer complex, composed of ??, ??, ??’, ??, ??, ??, and ??-COP subunits. This GTP-bound ARF5-coatomer assembly drives vesicle budding, capturing cargo receptors for retrograde transport to the endoplasmic reticulum. The cycle is terminated by GTP hydrolysis stimulated by ARF GAPs such as ARFGAP1, and is modulated by interactions with GGA adaptors and phospholipase D. Disruption of ARF5 by CRISPR/Cas9 thus impairs coatomer recruitment, destabilizing Golgi morphology and attenuating retrograde trafficking.
In Jurkat T cells, ARF5-dependent Golgi-ER trafficking underpins critical immune functions, including the delivery of newly synthesized receptors to the plasma membrane and the regulated secretion of cytokines. Knockout of ARF5 in this polyclonal population is expected to perturb Golgi architecture, alter surface receptor recycling dynamics, and affect secretory output??processes that are fundamental to T-cell activation, cytotoxicity, and communication. This model therefore offers a valuable tool for dissecting how membrane trafficking intersects with adaptive immunity and leukemic cell physiology.
This product is well-suited for a range of mechanistic and translational studies, spanning Golgi biology, intracellular trafficking, cancer cell signaling, and immunology. Researchers can employ immunofluorescence to visualize Golgi markers such as GM130 and giantin, Western blotting to assess coatomer subunit levels, flow cytometry to monitor receptor recycling, and ELISA-based secretion assays to quantify cytokine release. Further applications include vesicle trafficking assays using temperature-sensitive cargo and pharmacological perturbation of ARF pathways. For additional information or customized solutions, please contact Ascent Research.
